Moss, 16 April 2021

Gentian Diagnostics AS announces its results for the first quarter of 2021. The
highlights include:

* Record sales revenue of MNOK 19.6 in 1Q21, a 33 % organic growth. Reported
growth of 24 % on a currency neutral basis as 1Q20 includes revenues from the
subsidiary Pretect AS, which was divested in 2H20.

* Growth of 60 % versus Q1 last year in fCAL® turbo sales.

* Increased commercial momentum for GCAL®, displaying early signs of the next
revenue level, with new routine users in several European countries and new
distribution contracts.

* Expanded NT-proBNP development scope in order to enable industry
standardisation, expected to positively impact adoption rates. New launch date
set to 1Q22.

* Decision to apply for a listing of the shares at Oslo Børs Main market. It is
envisaged that a transfer of the listing from Euronext Growth to the main market
will take place towards the latter part of 1H21.

Please find the report and results presentation enclosed. The documents will
also be made available on www.gentian.no.


For further information, please contact:


Hilja Ibert

CEO, Gentian Diagnostics

E-mail: hilja.ibert@gentian.no

Cell Phone: +47 919 05 242



Njaal Kind

CFO, Gentian Diagnostics

E-mail: njaal.kind@gentian.no

Cell Phone. +47 919 06 525